Recently, placenta-specific 1 (PLAC1)-specific HLA-A0201-restricted TCR-engineered CD8+ T cells were developed to kill breast cancer cells by producing IFN-γ and TNF-α [128]. This evidence concerns the gene PLAC1 and breast carcinoma.